ENDRA Life Sciences Inc. and VGI Health Technology Limited announce the signing of a collaboration agreement to incorporate ENDRA's proprietary TAEUS technology to support patient screening and biomarker measurement during VGI's upcoming Phase 2 study of IVB001 in Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.02 AUD | -33.33% | -.--% | -.--% |
1st Jan change | Capi. | |
---|---|---|
-.--% | 18.27L | |
+5.33% | 11TCr | |
+12.11% | 11TCr | |
-12.56% | 2.23TCr | |
-3.70% | 2.19TCr | |
-6.03% | 1.86TCr | |
-35.21% | 1.81TCr | |
-10.86% | 1.7TCr | |
+5.10% | 1.37TCr | |
+37.57% | 1.24TCr |
- Stock Market
- Equities
- VTL Stock
- News VGI Health Technology Limited
- ENDRA Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology to Provide TAEUS for Patient Screening and Biomarker Measurement for Phase 2 Study